A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) in Adults with MDD at Imminent Risk of Suicide
The results of this open label study support the continued development of SLS-002. The randomized double-blind placebo-controlled part two of this trial was recently completed.
Authors
- Kimberly F Farrand (ORCID: https://orcid.org/0000-0003-0613-3085)
- Michael E. Thase (ORCID: https://orcid.org/0000-0002-6403-0861)
- Timothy Whitaker
Institutions
- Seelos Therapeutics (United States) (US)
- Philadelphia VA Medical Center (US)
Publication Details
- Journal
- Psychopharmacology Bulletin
- Published
- 2025-08-12
- DOI
- https://doi.org/10.64719/pb.4478
- Citations
- 2
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00